Archive for the ‘NeoStem Inc. NBS’ Category

Small Cap Voice Featured Client: NeoStem, Inc. (AMEX: NBS)

Wednesday, November 14th, 2007

NeoStem, Inc. (AMEX: NBS) is focused on the delivery of adult stem cell therapeutics to consumers concerned about their health. The Company is currently developing a nationwide network of adult stem cell collection centers that enable people to store their own unique stem cells for personal use later on if critical medical needs arise.

Currently hundreds of stem cell-based research programs and clinical trials are investigating the uses of these non-controversial adult stem cells. NeoStem has positioned itself as a leader in the national trend toward protecting one’s future health as the United States’ population continues to encounter serious health issues.

The Company’s business plan is a service model that is highly-scalable, consequently minimizing risks usually associated with most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem’s stem cell collection systems will be located in existing physician offices and medical facilities where professional care can be administered by trusted personal doctors and medical professionals.

Let us hear your thoughts: NeoStem, Inc. (AMEX: NBS)

Posted in NeoStem Inc. NBS, QualityStocks Stock Newsletters, SmallCapVoice | No Comments »

NeoStem (NBS) CEO Robin Smith to Ring Opening Bell at American Stock Exchange

Tuesday, October 23rd, 2007

NeoStem, Inc. (AMEX:NBS), a leading-edge healthcare company that seeks to capitalize on existing stem cell therapy applications, has announced that the company’s CEO Robin Smith, MD, will ring the opening bell at the American Stock Exchange on October 23rd, 2007.

Dr. Smith commented, “On behalf of all the employees and stockholders of NeoStem I am very gratified to take part in one of our financial community’s longest-standing traditions. NeoStem’s recent listing on the American Stock Exchange was an important milestone for us and we are excited to join the ranks of so many successful companies. We look forward to broadening our exposure within this great community of investors and to continue our work to build shareholder value as part of Amex.”

Let us hear your thoughts:

Posted in NeoStem Inc. NBS, QualityStocks Stock Newsletters | No Comments »

NeoStem, Inc’s (NBS) Video Details Promise of Current Adult Stem Cell Clinical Trials Targeting Widespread Diseases

Friday, October 19th, 2007

NeoStem, Inc. (NBS), a leading-edge healthcare company that intends to capitalize on existing stem cell applications, has released an investor video detailing the promise of adult stem cells.

Currently, clinical trials are underway to treat many of the world’s most intractable diseases through stem cell therapy. In fact, this industry is so prevalent that analysts predict that the adult stem cell industry will generate approximately $8.5 billion in revenue by 2016.

Robin Smith, MD, MBA, Chief Executive Officer of NeoStem, also details why the Company’s services should play a key role as the field of Regenerative Medicine fulfills the promise that many medical and scientific professionals anticipate.

“In the United States alone, there are nearly 700 ongoing studies currently underway to develop medical therapies based on adult stem cells, with nearly 200 of them focused on autologous applications,” said Dr. Smith during the video. “NeoStem believes there will be an overall growth in the adult stem cell industry, and it will be well positioned to capitalize on this growth.”

To view “The Promise of Stem Cells” investor video, please visit http://www.trilogy-capital.com/tcp/neostem

Let us hear your thoughts below:

Posted in NeoStem Inc. NBS, QualityStocks Stock Newsletters | No Comments »

SmallCapVoice Client: Neostem Inc. (NBS)

Monday, January 1st, 2007
 
NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need. Although adult stem cell therapies are generally not standard of care, the Company believes medicine is on the threshold of a plethora of such new therapies.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem cells – providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem’s methods. As the nation’s population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the national trend toward protecting one’s future health.

The Company’s business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.

For more information, please visit: http://www.qualitystocks.net/partners.php?partnerid=scvoice”

Posted in NeoStem Inc. NBS, QualityStocks Stock Newsletters, SmallCapVoice | No Comments »